CBU
ACAD icon

CIBC Bancorp USA’s Acadia Pharmaceuticals ACAD Stock Holding History

CIBC Bancorp USA’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$283K Buy
+13,267
New +$314K ﹤0.01% 1114

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

CIBC Bancorp USA's ACAD Position: Q3 2025 in Review

CIBC Bancorp USA opened a new position in Acadia Pharmaceuticals (ACAD) in Q3 2025: 13,267 shares worth $283K. The stake represents ﹤0.01% of the portfolio and ranks #1114 among its holdings.

333 funds tracked by Wall St. Rank hold ACAD as of Q3 2025.

  • CIBC Bancorp USA held 13,267 shares of Acadia Pharmaceuticals worth $283K as of Q3 2025.
  • Acadia Pharmaceuticals was a new CIBC Bancorp USA position in Q3 2025.
  • Acadia Pharmaceuticals made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q3 2025, its #1114 holding.
  • 333 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2025.

Based on CIBC Bancorp USA's 13F filing for Q3 2025, filed 12 Nov 2025.